Clinical trials: Resolution
Healthy
A Study in Healthy Men to Find Out How BI 425809 is Taken up and Handled by the Body
This trial intends to investigate the basic pharmacokinetics of BI 425809 and [14C]- radioactivity, including mass balance, excretion pathways and metabolism following a single oral dose of 25 mg BI 425809 (C-14) given to healthy…
- Trial name
- NCT03654170
- Testing
- BI 425809 mixed with [C-14] BI425809
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
COVID19
Study to Evaluate the Safety and Efficacy of VIRAZOLE® in Hospitalized Adult Participants With Respiratory Distress Due to COVID-19_#2
This study is a Phase 1, open label, non-randomized, two-arm interventional clinical trial to evaluate the safety and efficacy of Virazole® in hospitalized adult patients who have tested positive for COVID-19 and, as a result…
- Trial name
- NCT04356677
- Testing
- 50 mg/mL Virazole, 100 mg/mL Virazole
- Sponsor
- Bausch Health Americas, Inc.
Contact Lens Solution
Comparison of 3 Novel Contact Lens Solutions on the Basal Lamina
Three arm study comparing three novel contact lens solutions.
- Trial name
- NCT00691457
- Testing
- Opti-Free contact lens solution, ReNu Multiplus contact lens solution, Clear Care contact lens solution
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- Alcon Research
Cataract
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
Efficacy and Safety of Bromfenac Ophthalmic Solution in Cataract Surgery
- Trial name
- NCT00704418
- Testing
- Bromfenac
- Where
- United States
- Volunteers
- 156 people
- Sponsor
- Bausch & Lomb Incorporated
Cystic Fibrosis
Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults
An International Phase II, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of LAU-7b administered once-daily for 6 months for the treatment of CF.
- Trial name
- APPLAUD (NCT03265288)
- Testing
- LAU-7b
- Where
- 40 sites in United States, Australia and 1 more
- Volunteers
- 166 people
- Sponsor
- Laurent Pharmaceuticals Inc.
Healthy
Open-Label Absorption, Distribution, Metabolism, Excretion (ADME) and Pharmacokinetics (PK) Following a Single Oral Dose of AZD1236 in Healthy Male Subjects
The purpose of this study is to characterise the metabolism, excretion and pharmacokinetics of a single oral dose of [14C] AZD1236 in healthy male subjects.
- Trial name
- NCT01007929
- Testing
- 14C-AZD1236
- Where
- United Kingdom
- Volunteers
- 4 people, healthy volunteers welcome
- Sponsor
- AstraZeneca
Peritonitis, Intoxication
Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis
This study evaluates the efficacy and safety of Rheosorbilact®, solution for infusion ("Yuria-Pharm" LLC), in comparison with Ringer's Lactate, solution for infusion, in a complex therapy of peritonitis.
- Trial name
- NCT03771170
- Testing
- Rheosorbilact®, Ringer lactate
- Where
- 10 sites in Georgia, Moldova and 2 more
- Volunteers
- 180 people
- Sponsor
- Yuria-Pharm
Type2diabetes
The Attractive 2 Trial - Pharmacokinetics of ATR-258 Oral Capsule vs. Oral Solution Formulations in Healthy Volunteers
This is a single-centre, open-label, randomised, 2-period cross-over, Phase 1 comparative trial to assess the ATR-258 pharmacokinetic (PK) parameters of an oral capsule formulation in comparison with an oral solution formulation…
- Trial name
- Attractive 2 (NCT06432673)
- Testing
- ATR-258 Oral solution, ATR-258 Oral capsule
- Where
- Sweden
- Volunteers
- 21 people, healthy volunteers welcome
- Sponsor
- Atrogi AB
Dry Eye Syndrome
Assessing the Safety and Efficacy of AVX-012 in Subjects With Mild-to-moderate Dry Eye Syndrome
This is a first-in-human phase I/II randomized, double-blind, placebo (vehicle)-controlled, multicenter study to assess the Safety and Efficacy of AVX-012 Ophthalmic Solution in subjects with Mild-to-Moderate Dry Eye Syndrome.
- Trial name
- AVX012CT001 (NCT03162094)
- Testing
- AVX012 Ophthalmic Solution Low dose, AVX012 Ophthalmic Solution High dose
- Where
- 21 sites in Spain
- Volunteers
- 172 people
- Sponsor
- Avizorex Pharma, S.L.
Age-Related Macular Degeneration
A Safety and Efficacy Study of DE-120 Injectable Solution for Age-related Macular Degeneration
The purpose of the study is to evaluate the safety and efficacy of intravitreal (IVT) administration of DE-120 in subjects with treatment-naive active subfoveal choroidal neovascularization (CNV) secondary to age-related macular…
- Trial name
- VAPOR1 (NCT02401945)
- Testing
- DE-120, Aflibercept
- Where
- 14 sites in United States
- Volunteers
- 16 people
- Sponsor
- Santen Inc.
Limbal Stem Cell Deficiency (LSCD)
BRM421 Ophthalmic Solution in Patients With Limbal Stem Cell Deficiency
The goal of this program is to provide patients with Limbal Stem Cell Deficiency access to the BRM421 eye drops. Participants will: Use BRM421 two times a day for at least 12 weeks Visit the clinic monthly for checkups and tests
- Trial name
- NCT07422389
- Testing
- BRM421 Ophthalmic Solution, 0.06%
- Where
- United States
- Sponsor
- BRIM Biotechnology Inc.
Pulmonary Disease, Chronic Obstructive
A Single Dose Study to Determine the Excretion, Balance and Metabolic Disposition of Radiolabelled GW642444.
The purpose of this study is to characterise the metabolic disposition of radiolabelled GW642444 when administered orally.
- Trial name
- NCT01286831
- Testing
- [14C]GW642444
- Where
- Netherlands
- Volunteers
- 6 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Ureter Injury
3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution as an Aid for Ureteral Patency
To determine whether the use of 3,3'-Dioxo-2,2'-Bisindolylidene-5,5'-Disulfonate Disodium 0.8% Solution for injection provides a visualization advantage compared to saline when used as an aid in the determination of ureteral…
- Trial name
- UP (NCT04228445)
- Testing
- 3,3'-Dioxo-2,2'-bisindolylidene-5,5'-disulfonate disodium 0.8%, Saline spray
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Prove pharm
Focal Seizures
A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures
Cannabidiol oral solution (CBD-OS) is approved in the US for the treatment of seizures associated with Lennox-Gastaut syndrome (LGS), Dravet syndrome (DS), or Tuberous sclerosis complex (TSC) in patients 1 year of age and older.
- Trial name
- NCT07233239
- Testing
- CBD-OS
- Where
- 24 sites in United States
- Volunteers
- 100 people
- Sponsor
- Jazz Pharmaceuticals
Cystic Fibrosis
Safety of Tobramycin Inhalation Powder (TIP) vs Tobramycin Solution for Inhalation in Patients With Cystic Fibrosis
This study compares the safety of the tobramycin solution for inhalation with the tobramycin dry powder formulation, used with a simple inhaler
- Trial name
- EAGER (NCT00388505)
- Testing
- Tobramycin Inhalation Powder, Tobramycin Solution for Inhalation
- Where
- 72 sites in United States, Australia and 12 more
- Volunteers
- 517 people
- Sponsor
- Novartis Pharmaceuticals
Glaucoma, Ocular Hypertension
Safety and Efficacy of Triple Combination Therapy in Patients With Glaucoma or Ocular Hypertension
This study will investigate the safety and efficacy of Triple Combination Therapy (bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution) in patients with glaucoma or ocular hypertension who have elevated…
- Trial name
- NCT01216943
- Testing
- bimatoprost/brimonidine tartrate/timolol fixed combination ophthalmic solution
- Where
- India
- Volunteers
- 126 people
- Sponsor
- Allergan
Dry Eye
Study to Compare the Efficacy of the Ophthalmic Solution Humylub Ofteno® PF With Hyabak® and Lagricel Ofteno® PF as Treatment for Dry Eye.
Phase IV, non inferiority, controlled, open, multicenter clinical study to compare the efficacy of the Ophthalmic Solution Humylub Ofteno® PF against Hyabak® and Lagricel Ofteno® PF applied quater in die (QID) for 30 days in…
- Trial name
- PRO-087 (NCT04702776)
- Testing
- Sodium hyaluronate 0.1%/chondroitin sulfate 0.18%, Sodium hyaluronate 0.15%, Sodium hyaluronate 0.4%
- Where
- Mexico
- Volunteers
- 182 people
- Sponsor
- Laboratorios Sophia S.A de C.V.
Healthy
Metabolism and Pharmacokinetics of Oral Solution of [14C]-BI 201335 in Healthy Male Volunteers
Study to determine the pharmacokinetics (PK) of BI 201335 and total radioactivity including excretion mass balance, excretion pathways and metabolism following the oral administration of [14C]-BI 201335 at steady state.
- Trial name
- NCT02182349
- Testing
- BI 201335 NA soft gelatin capsule, [14C]-BI 201335 NA radiolabelled drug
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Boehringer Ingelheim
Pulmonary Disease, Chronic Obstructive
Postmarketing Surveillance Study to Assess Handling and Patient Satisfaction on Berodual® Respimat® Solution for Inhalation in Patients With Chronic Obstructive Pulmonary Disease
New perceptions about handling and patient satisfaction of the everyday use of Berodual® Respimat® in patients with chronic obstructive lung disease (COLD).
- Trial name
- NCT02231320
- Testing
- Berodual® Respimat® - inhaler
- Volunteers
- 236 people
- Sponsor
- Boehringer Ingelheim
Healthy Subjects
A Single Dose Crossover Study In Healthy Subjects To Evaluate Different Formulations Of PF-06882961
This open label study will evaluate the pharmacokinetics (PK) following single oral doses of different formulations of PF-06882961, including controlled release (CR) tablets at 2 release rates (long and short duration), an…
- Trial name
- NCT03492697
- Testing
- PF-06882961 Immediate Release Tablet, PF-06882961 Controlled Release Tablet (long), PF-06882961 Controlled Release Tablet (short)
- Where
- United States
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Pfizer
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.